These guides are AI-generated educational summaries — not legal or medical advice.
C&P Exam Prep: Ovarian Cancer (Malignant Neoplasm)
DBQ Overview
Interview + Physical- Form Name
- Gynecological_Conditions
- Form Code
- Gynecological_Conditions
- Page Count
- 10
- Examiner Type
- Gynecologist, Gynecologic Oncologist, or appropriate clinician
- Estimated Duration
- 30-45 minutes
- Exam Format
- Interview + Physical
What to Expect During Your Exam
Exam Overview
To document the current nature, severity, treatment status, residuals, and functional impact of ovarian cancer (malignant neoplasm, DC 7632) for VA disability rating purposes. The examiner will assess whether the cancer is active or in remission, the extent of treatment received or ongoing, any residuals or complications, and the overall impact on daily functioning and quality of life.
What the examiner evaluates:
- Confirmed diagnosis of ovarian cancer including histological type, stage, and grade
- Whether cancer is currently active, in partial remission, or complete remission
- Whether cancer is primary or metastatic/secondary, and if secondary, the primary site
- All treatments received: surgery (oophorectomy, debulking), chemotherapy (antineoplastic agents), radiation therapy, targeted therapy, immunotherapy, hormonal therapy
- Treatment dates, facilities, completion or anticipated completion dates
- Residuals and complications of the cancer and its treatment (e.g., neuropathy, lymphedema, fatigue, bowel/bladder dysfunction, fistulas, incontinence)
- Pain severity (mild, moderate, severe) and frequency of pain episodes
- Menstrual disturbances, amenorrhea, dysmenorrhea, or irregular bleeding
- Pelvic pressure, pelvic pain, or abdominal symptoms
- Incontinence requiring absorbent material and frequency of pad changes
- Laboratory values including hemoglobin (HGB) and hematocrit (HCT) for anemia assessment
- Presence of fistulas (urethrovaginal or other)
- Impact on occupational functioning and activities of daily living
- Any additional gynecological diagnoses or comorbidities related to the claimed condition
- Nexus (connection) between service and the condition if nexus is in question
The examination will typically include both an interview component and a physical/pelvic examination. Some examinations may be conducted via telehealth or records review if an in-person exam is not feasible. You have the right to request that the exam be conducted in person. Bring a support person if desired; notify the examiner of their presence. The examiner is required to review your claims file (C-file) and all available treatment records before or during the exam.
Typical duration: 30-45 minutes
Hemoglobin (HGB) and Hematocrit (HCT)
Blood oxygen-carrying capacity; used to assess anemia caused by cancer, cancer treatment (chemotherapy/radiation), or related bleeding. Critical for rating anemia as a secondary condition.
What to expect:
The examiner will review recent laboratory results or may order a blood draw. Bring copies of your most recent CBC (complete blood count) results from your treating oncologist or primary care provider.
Key thresholds:
- HGB < 7.1 g/dL or HCT < 21% — Severe anemia - supports highest rating levels for anemia as a secondary/associated condition
- HGB 7.1-10.0 g/dL or HCT 21-30% — Moderate anemia - supports intermediate rating for associated anemia
- HGB > 10.0 g/dL or HCT > 30% — Mild or no anemia - lower rating impact for anemia specifically
Tips:
- Request lab results from your oncologist within 30 days of your C&P exam if possible
- Note the date of lab results - examiners will record this on the DBQ
- If anemia fluctuates, bring documentation of your lowest recorded values and the dates they occurred
- Mention if anemia has required transfusions or erythropoietin treatment, as this indicates severity
Pain considerations: Severe anemia from chemotherapy can cause debilitating fatigue and weakness that independently limits functioning - describe this as a distinct symptom cluster separate from cancer pain.
Pain Severity Assessment (Mild / Moderate / Severe)
The examiner will determine whether the veteran experiences mild, moderate, or severe pain associated with ovarian cancer or its treatment. Under DC 7632 and 38 CFR 4.116, pain level is a direct rating factor for malignant neoplasms.
What to expect:
The examiner will ask you to characterize your pain using a 0-10 scale and will categorize it as mild, moderate, or severe. They will also document frequency. Be prepared to describe pain on your worst days, not just an average day.
Key thresholds:
- Severe pain — Supports higher rating levels; contributes to a 100% rating when combined with active disease or continuous treatment requirement
- Moderate pain — Supports intermediate rating levels; must be well-documented with frequency and functional impact
- Mild pain — Supports lower rating levels; ensure frequency is also documented to avoid underrating
Tips:
- Rate your pain on your worst day, not your best day or average day - per M21-1 guidance, the DBQ captures worst-day functioning
- Describe both the location and character of pain (e.g., pelvic, abdominal, back, neuropathic burning from chemotherapy)
- Specify frequency: constant, daily, several times per week, or episodic with triggers
- Include pain from treatment side effects (neuropathy, joint pain from hormonal therapy) as part of your overall pain picture
- Mention if pain limits specific activities such as sitting, walking, working, or sleeping
Pain considerations: Pain from ovarian cancer can be multifactorial: tumor pressure, post-surgical adhesions, peripheral neuropathy from platinum-based chemotherapy, and bone pain from metastases or hormonal changes. Each type should be described separately to the examiner.
Incontinence / Absorbent Material Assessment
The examiner documents whether urinary or fecal incontinence is present and the severity as measured by the number of absorbent pad changes required per day. This affects rating for urinary or fecal incontinence as residuals of ovarian cancer treatment.
What to expect:
The examiner will ask whether you experience incontinence, whether you use absorbent pads or diapers, and how many times per day you change them. They may also ask about fistulas (abnormal connections between urinary/bowel tract and vagina).
Key thresholds:
- Requires absorbent material changed more than 4 times per day — Highest severity tier for incontinence-related ratings
- Requires absorbent material changed 2-4 times per day — Moderate severity tier
- Requires absorbent material changed less than 2 times per day — Lower severity tier
- Does not require or use absorbent material — Incontinence not rated or rated at minimum level
Tips:
- Count actual pad changes on your worst days, not your best days
- Include pads used for both urinary and fecal incontinence if both are present
- Document if incontinence requires use of a catheter, colostomy bag, or other appliance - this is separately rated
- Note the cause: surgical damage to bladder/bowel, radiation damage, fistula formation, or pelvic floor weakness
Pain considerations: Incontinence can cause significant social isolation, embarrassment, and psychological distress - communicate the full functional and social impact to the examiner, not just the number of pad changes.
Rating Criteria Breakdown
| Rating % | Criteria | Key Symptoms |
|---|---|---|
| 100% | Active malignancy, or during and following treatment with antineoplastic chemotherapy, radiation therapy, or surgery. Under 38 CFR 4.29 and 4.30, a temporary 100% rating is assigned during active treatment and is continued for a specified period following treatment completion. Additionally, a 100% rating applies when symptoms are not controlled despite continuous treatment, or when the condition results in severe systemic involvement (e.g., widespread metastases, severe pain, severe constitutional symptoms). |
CFR: Under 38 CFR 4.116 (DC 7632) and the provisions of 38 CFR 4.29/4.30, a veteran with active ovarian cancer or undergoing antineoplastic therapy receives a 100% rating. This rating continues for a mandatory evaluation period (typically 6 months) after treatment completion, after which the condition is re-evaluated for residuals. |
| 100% | Post-treatment 100% rating continuation: Following completion of antineoplastic therapy (chemotherapy, radiation, or surgery), the 100% rating is continued for a mandatory minimum period per 38 CFR 4.29 (chemotherapy/radiation: 6 months post-completion) and 38 CFR 4.30 (surgery). After this period, the condition is re-evaluated based on residuals. Veterans should be aware that VA will schedule a future examination approximately 6 months after treatment ends. |
CFR: 38 CFR 4.29 mandates a minimum 6-month continuation of the 100% rating following completion of chemotherapy or radiation therapy. 38 CFR 4.30 provides similar protections following surgery. The veteran should not be reduced below 100% during this mandatory continuation period. |
| 30% | Following the mandatory post-treatment continuation period, if the cancer is in complete remission with no evidence of disease (NED), the rating is evaluated based on residuals under the appropriate diagnostic code(s). A minimum 30% rating may apply based on documented residuals such as surgical removal of an ovary (oophorectomy), peripheral neuropathy from chemotherapy, lymphedema, bowel/bladder dysfunction, fatigue, hormonal changes from surgical menopause, or other lasting complications. Each residual may be separately rated. |
CFR: Under 38 CFR 4.116, after the mandatory continuation period, residuals of ovarian cancer and its treatment are rated under the most analogous diagnostic code(s). For example: complete oophorectomy (DC 7619 - 30%), peripheral neuropathy (DC 8620/8720 series), incontinence, or other organ-specific residuals. Each ratable residual should be separately claimed and evaluated. |
100% Active malignancy, or during and following treatment with an ...
Active malignancy, or during and following treatment with antineoplastic chemotherapy, radiation therapy, or surgery. Under 38 CFR 4.29 and 4.30, a temporary 100% rating is assigned during active treatment and is continued for a specified period following treatment completion. Additionally, a 100% rating applies when symptoms are not controlled despite continuous treatment, or when the condition results in severe systemic involvement (e.g., widespread metastases, severe pain, severe constitutional symptoms).
Key Symptoms
- Active ovarian cancer (any stage) with or without metastasis
- Currently undergoing chemotherapy (antineoplastic agents)
- Currently undergoing radiation therapy
- Post-surgical recovery period following debulking, oophorectomy, or other cancer surgery
- Severe pain not controlled by continuous treatment
- Severe constitutional symptoms: profound fatigue, weight loss, cachexia
- Widespread metastases to lymph nodes, peritoneum, liver, lungs, or other organs
- Inability to perform activities of daily living due to cancer or treatment effects
CFR: Under 38 CFR 4.116 (DC 7632) and the provisions of 38 CFR 4.29/4.30, a veteran with active ovarian cancer or undergoing antineoplastic therapy receives a 100% rating. This rating continues for a mandatory evaluation period (typically 6 months) after treatment completion, after which the condition is re-evaluated for residuals.
100% Post-treatment 100% rating continuation: Following completio ...
Post-treatment 100% rating continuation: Following completion of antineoplastic therapy (chemotherapy, radiation, or surgery), the 100% rating is continued for a mandatory minimum period per 38 CFR 4.29 (chemotherapy/radiation: 6 months post-completion) and 38 CFR 4.30 (surgery). After this period, the condition is re-evaluated based on residuals. Veterans should be aware that VA will schedule a future examination approximately 6 months after treatment ends.
Key Symptoms
- Recent completion of chemotherapy (within 6 months)
- Recent completion of radiation therapy (within 6 months)
- Recent surgical treatment for ovarian cancer (within 6 months)
- Ongoing treatment side effects persisting after treatment completion
- Continued monitoring with CA-125 or imaging pending
CFR: 38 CFR 4.29 mandates a minimum 6-month continuation of the 100% rating following completion of chemotherapy or radiation therapy. 38 CFR 4.30 provides similar protections following surgery. The veteran should not be reduced below 100% during this mandatory continuation period.
30% Following the mandatory post-treatment continuation period, ...
Following the mandatory post-treatment continuation period, if the cancer is in complete remission with no evidence of disease (NED), the rating is evaluated based on residuals under the appropriate diagnostic code(s). A minimum 30% rating may apply based on documented residuals such as surgical removal of an ovary (oophorectomy), peripheral neuropathy from chemotherapy, lymphedema, bowel/bladder dysfunction, fatigue, hormonal changes from surgical menopause, or other lasting complications. Each residual may be separately rated.
Key Symptoms
- Complete surgical menopause resulting from bilateral oophorectomy
- Peripheral neuropathy (hands/feet numbness, tingling, burning) from platinum-based chemotherapy
- Chemotherapy-induced cognitive impairment ('chemo brain')
- Lymphedema of lower extremities from lymph node dissection
- Bowel dysfunction: diarrhea, constipation, fecal urgency from radiation or surgery
- Bladder dysfunction: urgency, frequency, incontinence from radiation or surgical damage
- Adhesions or bowel obstruction from prior surgery
- Fatigue that persists after treatment completion
- Sexual dysfunction from surgical or treatment-related changes
- Psychological impact: depression, anxiety, PTSD related to cancer diagnosis and treatment
CFR: Under 38 CFR 4.116, after the mandatory continuation period, residuals of ovarian cancer and its treatment are rated under the most analogous diagnostic code(s). For example: complete oophorectomy (DC 7619 - 30%), peripheral neuropathy (DC 8620/8720 series), incontinence, or other organ-specific residuals. Each ratable residual should be separately claimed and evaluated.
How to Describe Your Symptoms
Pain (Pelvic, Abdominal, Neuropathic)
How to describe:
Describe all pain associated with ovarian cancer and its treatment. Separate tumor-related pain from surgical pain from neuropathic pain (burning/tingling in hands and feet from chemotherapy). Rate each on a 0-10 scale and describe frequency (constant, daily, several times per week), location, and what makes it better or worse. Use specific activity limitations to illustrate severity.
Worst-day example:
“On my worst days - which happen several times a week - I have severe pelvic pressure and deep abdominal pain that rates 8 out of 10. I cannot sit for more than 20 minutes, I cannot do household tasks, and I have to lie down for hours. Additionally, my feet burn and feel numb from chemotherapy neuropathy, making it painful to walk more than half a block.”
What the examiner listens for:
Differentiation between mild, moderate, and severe pain; frequency of severe episodes; functional limitations caused by pain; whether pain is controlled by current medications or uncontrolled despite treatment; impact on sleep, work, and daily activities.
Understatements to avoid:
Do not say 'my pain is manageable' without clarifying that it requires heavy pain medication to achieve that level. Do not describe only your good days - M21-1 instructs examiners to rate based on the full picture including worst-day functioning.
Treatment Status and Ongoing Therapy
How to describe:
Clearly state whether you are currently in active treatment (chemotherapy, radiation, targeted therapy, immunotherapy, maintenance therapy such as PARP inhibitors or bevacizumab), have recently completed treatment, or are in surveillance/remission. Know your exact treatment dates, facilities, and drug regimens if possible. The examiner will ask whether treatment is completed or ongoing.
Worst-day example:
“I completed my sixth cycle of carboplatin and paclitaxel chemotherapy on [date] at [facility]. I am currently on maintenance olaparib (PARP inhibitor). During active chemotherapy, I was completely disabled - I could not leave my home for weeks at a time, required assistance with personal care, and was hospitalized twice for neutropenic fever.”
What the examiner listens for:
Specific treatment modalities, dates of initiation and completion, whether treatment is completed or ongoing, whether there is evidence of recurrence requiring additional treatment, and the severity of treatment-related side effects.
Understatements to avoid:
Do not minimize the severity of chemotherapy side effects as 'just the typical side effects.' Document each side effect that limits your functioning. Do not forget to mention maintenance therapy - being on maintenance PARP inhibitors or bevacizumab means treatment is NOT completed.
Cancer Status (Active vs. Remission) and Recurrence
How to describe:
Be precise about your current disease status as documented in your medical records. Active disease, partial response to treatment, complete clinical response, NED (no evidence of disease), or recurrence after remission all carry different rating implications. If you have had a recurrence, describe when it was detected, how, and what treatment followed.
Worst-day example:
“My oncologist confirmed complete clinical remission following surgery and chemotherapy, but my CA-125 levels began rising again at my 18-month surveillance visit, and a PET scan showed recurrent peritoneal disease. I am now back on active chemotherapy for my second recurrence.”
What the examiner listens for:
Whether the cancer is primary or metastatic, the current disease status at the time of examination, history of recurrences, whether surveillance is ongoing, and the most recent imaging or tumor marker results.
Understatements to avoid:
Do not assume the examiner has reviewed all your oncology records. Bring copies of your most recent imaging reports, CA-125 trending results, and oncology notes to clearly establish current disease status.
Residuals After Treatment - Physical
How to describe:
Comprehensively describe every lasting physical effect of both the cancer and its treatment. These residuals are separately ratable conditions. Common residuals include: peripheral neuropathy, lymphedema, surgical menopause symptoms, bowel dysfunction, bladder dysfunction (urgency, incontinence), abdominal adhesions, fatigue, and changes in body composition.
Worst-day example:
“Since completing treatment, I have permanent numbness and burning in both feet from chemotherapy neuropathy - I fall frequently and cannot walk safely on uneven ground. I also experience severe hot flashes and night sweats from surgical menopause that disrupt my sleep every night, and I have urinary urgency incontinence requiring 3-4 pad changes per day due to radiation damage to my bladder.”
What the examiner listens for:
Specific residual conditions that are separately diagnosable and ratable; impact on mobility, continence, sleep, and daily activities; whether residuals require ongoing treatment; objective findings on physical examination.
Understatements to avoid:
Do not lump all residuals together as 'some side effects from chemo.' Name each residual specifically. Do not forget that surgical menopause resulting from bilateral oophorectomy is itself a separately ratable condition (DC 7619).
Functional and Occupational Impact
How to describe:
Describe in concrete terms how ovarian cancer and its treatment have affected your ability to work, perform household tasks, maintain relationships, exercise, and care for yourself. Use specific time-based examples and quantify limitations where possible (e.g., 'I can only stand for 10 minutes before pain forces me to sit,' or 'I missed 60 days of work during chemotherapy').
Worst-day example:
“During active treatment I was completely unable to work and required my spouse to assist me with bathing and meal preparation. Even now in remission, my neuropathy prevents me from performing the computer work my job requires, and my fatigue limits me to about 4 hours of productive activity per day before I must rest. I have not been able to return to full-time employment.”
What the examiner listens for:
Specific occupational limitations, loss of income or employment, need for assistance with activities of daily living, impact on social and family functioning, use of assistive devices, and whether the veteran has been granted TDIU (total disability individual unemployability).
Understatements to avoid:
Do not say 'I manage' without explaining the cost of that management (extra rest, medication, assistance from others, giving up activities). Do not assume functional limitations are obvious from a diagnosis alone - spell them out explicitly.
Incontinence and Absorbent Material Use
How to describe:
If you experience urinary or fecal incontinence from treatment (radiation damage, surgical damage, fistulas), describe the type, frequency, and severity. Be specific about the number of pads or absorbent products you use per day on your worst days. Note if you use any appliances such as a catheter, urostomy, or colostomy bag.
Worst-day example:
“On bad days - which happen at least three to four days per week - I experience urinary urgency incontinence and must change my absorbent pad five or more times. I have had two episodes of urethrovaginal fistula symptoms confirmed by my urologist as a consequence of pelvic radiation. This prevents me from leaving home for extended periods and causes me significant social embarrassment and isolation.”
What the examiner listens for:
Whether incontinence is present, its cause (radiation, surgery, fistula), the number of pad changes per day on worst days, whether appliances are required, and the social and functional impact of incontinence.
Understatements to avoid:
Do not underreport pad usage out of embarrassment. The number of pad changes is a direct rating criterion. Bring a note from your urologist or gynecologist documenting the diagnosis and treatment of incontinence if available.
Common Mistakes to Avoid
Describing only your average or best days rather than your worst days
VA rating criteria under M21-1 and 38 CFR 4.7 are based on the full picture of disability severity, including worst-day functioning. Examiners are instructed to consider the full range of symptoms. Veterans who describe only moderate days systematically underrepresent their disability.
Instead: Always clarify: 'On my worst days, which happen X times per week, my symptoms are...' and describe those worst days in specific, concrete detail. Bring a symptom diary if possible.
Impact: All rating levels - particularly the distinction between moderate and severe pain, and between continuous treatment required vs. not required
Failing to report all treatment side effects and residuals as separate conditions
Each residual from ovarian cancer treatment (neuropathy, lymphedema, incontinence, surgical menopause, etc.) may be separately ratable under its own diagnostic code. Veterans who mention these only in passing lose the opportunity for separate ratings that combine toward a higher overall combined rating.
Instead: Before the exam, prepare a comprehensive list of every lasting physical and mental health effect from your cancer or treatment. Ask the examiner to specifically document each one. Consider filing separate claims for major residuals such as peripheral neuropathy (DC 8620/8720), urinary incontinence (DC 7542), and surgical menopause (DC 7619).
Impact: Post-remission rating - determines total combined disability rating after mandatory 100% period ends
Assuming the examiner has thoroughly reviewed your medical records before the exam
Examiners may be working under time pressure and may not have had time to review voluminous oncology records. Critical facts such as recurrence history, CA-125 trends, or recent imaging results may be missed if not brought to the examiner's attention.
Instead: Bring a one-page written summary of your cancer diagnosis, treatment history, current status, and key residuals. Also bring copies of your most recent oncology notes, imaging reports, and lab results. Hand these to the examiner at the start of the appointment.
Impact: Active disease vs. remission determination - critical for 100% rating
Not mentioning maintenance therapy as ongoing 'treatment'
Many ovarian cancer patients receive maintenance therapy (PARP inhibitors like olaparib, niraparib; or bevacizumab) after completing primary chemotherapy. Veterans and examiners may not characterize this as 'treatment,' but it is antineoplastic therapy that should support continuation of a 100% rating under 38 CFR 4.29.
Instead: Explicitly tell the examiner: 'I am currently receiving maintenance antineoplastic therapy - [drug name] - since [date].' Bring documentation of the prescription and the oncologist's rationale for maintenance therapy.
Impact: 100% rating continuation - maintenance therapy means treatment is NOT completed
Failing to report psychological and cognitive impacts of cancer and treatment
Depression, anxiety, PTSD related to cancer diagnosis, and chemotherapy-induced cognitive impairment ('chemo brain') are common, significantly disabling, and separately ratable. Veterans who do not mention these miss an opportunity for additional service-connected ratings.
Instead: Report any changes in memory, concentration, word-finding, mood, sleep, or anxiety that began with or after your cancer diagnosis or treatment. Request a separate mental health referral if the examiner does not address these. Consider filing a separate claim for mental health conditions secondary to ovarian cancer.
Impact: Combined rating - mental health conditions can significantly increase total combined disability percentage
Using medical jargon or vague terms like 'I have some issues' without specific functional descriptions
The DBQ requires the examiner to select specific functional levels and severity tiers. Vague descriptions do not give the examiner enough information to accurately complete the form at the appropriate severity level.
Instead: Use specific, functional language: 'I cannot walk more than one block without stopping due to neuropathy pain' rather than 'my feet bother me.' Quantify limitations in terms of time, distance, frequency, and activity.
Impact: All rating levels - specificity drives accurate DBQ completion
Not documenting the social and occupational impact of incontinence
Urinary and fecal incontinence caused by radiation or surgical damage are significant quality-of-life impairments. Veterans who mention incontinence without describing its social impact (inability to leave home, social isolation, embarrassment, employment limitations) may receive lower ratings than warranted.
Instead: Describe specific activities you cannot do because of incontinence: traveling, attending events, working certain jobs, exercising. State the exact number of pad changes required on your worst days.
Impact: Incontinence-related rating under urinary/fecal incontinence diagnostic codes
Prep Checklist
Before Your Exam
Day Of
During the Exam
After the Exam
Your Rights During a C&P Exam
- You have the right to a C&P examination conducted by a qualified examiner with appropriate expertise in gynecological conditions, including gynecologic oncology. If assigned an unqualified examiner, request reassignment through your VSO or VA regional office.
- You have the right to request that your C&P examination be conducted in person rather than via telehealth or records review, if an in-person exam is medically appropriate and available.
- You have the right to audio record your C&P examination in most states with advance notice to VA. Check current VA policy and state law before the exam and provide written notice to VA prior to the appointment.
- You have the right to bring a support person (spouse, family member, VSO representative, or patient advocate) to your C&P examination. Notify the examiner of their presence at the beginning of the appointment.
- You have the right to request a same-gender examiner or a chaperone during any physical or pelvic examination. Make this request in writing to VA before the scheduled exam date.
- You have the right to receive a copy of the completed DBQ and all examination reports through the Freedom of Information Act (FOIA), your MyHealtheVet account, or by requesting your claims file from VA.
- You have the right to submit a written rebuttal to an inadequate, inaccurate, or unfavorable C&P examination report, including by submitting a private independent medical examination (IME) or nexus letter from a qualified clinician.
- You have the right to a 100% disability rating during active antineoplastic treatment (chemotherapy, radiation, surgery) and for the mandatory continuation period following treatment completion under 38 CFR 4.29 and 4.30.
- You have the right to have all residuals and complications of ovarian cancer and its treatment separately evaluated and rated under the most favorable applicable diagnostic codes under 38 CFR 4.7 (benefit of the doubt).
- Under 38 CFR 3.102, VA must apply the benefit of the doubt in your favor when the evidence is approximately balanced. You are not required to prove your case beyond a reasonable doubt - only that service connection is at least as likely as not.
- You have the right to representation by an accredited Veterans Service Organization (VSO), claims agent, or VA-accredited attorney at no cost (VSOs) or regulated fee (attorneys/agents) at any stage of your claim.
Related Conditions
- Oophorectomy (Surgical Removal of Ovary) Ovarian cancer treatment frequently requires partial or complete surgical removal of one or both ovaries. Bilateral oophorectomy is separately ratable under DC 7619 (30% minimum) and results in surgical menopause with its own additional residuals. File a separate claim for oophorectomy as secondary to ovarian cancer.
- Peripheral Neuropathy (Chemotherapy-Induced) Platinum based chemotherapy agents (carboplatin, cisplatin) commonly used for ovarian cancer cause peripheral neuropathy affecting the hands and feet. This is a separately ratable residual condition under DC 8620 (sciatic nerve) or appropriate nerve diagnostic codes. Document and claim separately as secondary to ovarian cancer treatment.
- Urinary Incontinence (Radiation or Surgical) Pelvic radiation therapy and surgical procedures for ovarian cancer can cause permanent damage to the bladder, urethra, and pelvic floor resulting in urinary incontinence. This is separately ratable under DC 7542 (neurogenic bladder) or other urinary diagnostic codes. Document and claim separately as secondary to ovarian cancer treatment.
- Anemia (Chemotherapy or Disease-Induced) Ovarian cancer and its treatment (especially chemotherapy) commonly cause anemia through bone marrow suppression or chronic disease. Anemia may be separately ratable under DC 7700 series based on HGB/HCT levels. Bring recent CBC results to your C&P exam and claim anemia separately if it persists.
- Major Depressive Disorder / Anxiety (Secondary to Cancer) A diagnosis of ovarian cancer and the associated treatment burden, physical changes, fear of recurrence, and functional limitations commonly cause or exacerbate depression and anxiety disorders. These are separately ratable under DC 9434 (MDD) or related mental health codes as conditions secondary to ovarian cancer. File a separate claim for mental health conditions secondary to your ovarian cancer.
- Lymphedema (Lower Extremity, Post-Surgical) Pelvic and para aortic lymph node dissection performed as part of ovarian cancer staging or cytoreductive surgery can cause lymphedema of the lower extremities. This is separately ratable under DC 7199 7120 (analogous to varicose veins) or other appropriate codes. Document with documentation from a lymphedema therapist and claim separately.
- Irritable Bowel / Bowel Dysfunction (Radiation-Induced) Pelvic radiation therapy for ovarian cancer can cause chronic radiation enteritis or proctitis resulting in diarrhea, urgency, bowel incontinence, or stricture. These are separately ratable under DC 7319 (irritable bowel syndrome) or analogous digestive system codes. Document with gastroenterology records and claim separately.
- Surgical Menopause / Ovarian Insufficiency Bilateral oophorectomy performed as ovarian cancer treatment results in immediate surgical menopause with severe hot flashes, night sweats, sleep disruption, bone loss, cardiovascular risk, and cognitive changes. This may be considered within the oophorectomy rating (DC 7619) or evaluated through its systemic effects. Ensure all menopause related symptoms are comprehensively documented.
Get Personalized C&P Exam Preparation
Upload your medical records for AI-powered prep that maps YOUR symptoms to the exact DBQ fields your examiner will evaluate.
This C&P exam preparation guide is for educational purposes only and does not constitute legal, medical, or claims advice. Always consult with a qualified Veterans Service Organization (VSO) representative or VA-accredited attorney for guidance specific to your claim. Never exaggerate, minimize, or fabricate symptoms during a C&P examination.